Provided by Tiger Trade Technology Pte. Ltd.

Intercept Pharmaceuticals

19.00
0.0000
Volume:- -
Turnover:75.31M
Market Cap:794.69M
PE:-12.84
High:19.00
Open:19.00
Low:19.00
Close:19.00
52wk High:21.86
52wk Low:8.82
Shares:41.83M
Float Shares:36.70M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4798
EPS(LYR):6.56
ROE:-64.02%
ROA:-7.23%
PB:11.06
PE(LYR):2.90

Loading ...

Company Profile

Company Name:
Intercept Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.